Global healthcare investment firm OrbiMed Advisors invested $4.3 million in Otic Pharma, an Israeli company that develops foam-based treatments for ear diseases. “Foam-Otic”, according to the company, is considered to be a more efficient drug than ear drops, with lower and less frequent doses. Otic Pharma is about to complete a clinical trial to test the safety and efficacy of its foam treatment. The company is also developing veterinary treatments for pets. The financing will enable it to begin a trial for its veterinary product. View and share
Subscribe to NoCamels weekly newsletter and get our top stories
Related posts
Top Tel Aviv Hospital Using AI In Neurological Therapy
April 18, 2024
Israel Foodtech Firms Meet UK Retailers, Investors In London
April 17, 2024
Facebook comments